C. Negrier, Orphanet: Hemophilie. orphanet Available at: http://www, orpha.net, p.18, 2016.

. Inserm-l-'hémophilie,-une-maladie-hémorragique-héréditaire, Available at: http://www.inserm.fr/thematiques/physiopathologie-metabolisme-nutrition/dossiers-dinformation/hemophilie, 2015.

R. Francecoag-invs, Available at: http://www.francecoag.org/SiteWebPublic/public/stats/stats_page, pp.2-3, 2015.

G. D. Boon, An Overview of Hemostasis, Toxicologic Pathology, vol.257, issue.2, pp.170-179, 1993.
DOI : 10.1177/019262339302100209

B. Dahlbäck, Blood coagulation. The Lancet 355, pp.1627-1632, 2000.

P. H. Bolton-maggs, K. J. Pasi, A. Haemophilias, and B. , Haemophilias A and B, The Lancet, vol.361, issue.9371, pp.1801-1809, 2003.
DOI : 10.1016/S0140-6736(03)13405-8

S. V. Kaveri, Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells, Haemophilia, vol.109, issue.Suppl. 4, pp.61-64, 2007.
DOI : 10.1111/j.1365-2516.2007.01575.x

C. Esmon, Regulation of blood coagulation, Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol.1477, issue.1-2, pp.349-360, 2000.
DOI : 10.1016/S0167-4838(99)00266-6

P. Codine, N. Kotzki, and J. Pélissier, Coagulation, thrombose et médecine physique, 2005.

A. Pierce and J. Pittet, Practical Understanding of Hemostasis and Approach to the Bleeding Patient in the Operating Room, Advances in Anesthesia, vol.32, issue.1, pp.1-21, 2014.
DOI : 10.1016/j.aan.2014.08.009

P. J. Fay and P. Jenkins, Mutating factor VIII: lessons from structure to function, Blood Reviews, vol.19, issue.1, pp.15-27, 2005.
DOI : 10.1016/j.blre.2004.02.003

A. B. Payne, C. H. Miller, F. M. Kelly, J. Michael-soucie, and W. Craig-hooper, The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource, Human Mutation, vol.29, issue.1, pp.2382-2392, 2013.
DOI : 10.1002/humu.22247

W. Wang, Y. J. Wang, and D. N. Kelner, Coagulation factor VIII: structure and stability, International Journal of Pharmaceutics, vol.259, issue.1-2, pp.1-15, 2003.
DOI : 10.1016/S0378-5173(03)00227-8

P. J. Lenting, O. D. Christophe, and P. Guéguen, The disappearing act of factor VIII, Haemophilia, vol.118, issue.102, pp.6-15, 2010.
DOI : 10.1111/j.1365-2516.2008.01864.x

F. Peyvandi, Genetic diagnosis of haemophilia and other inherited bleeding disorders, Haemophilia, vol.90, issue.s3, pp.82-89, 2006.
DOI : 10.1182/blood-2003-01-0116

. Porteuses, La transmission de l'hémophilie -World Federation of Hemophilia Available at: http://www.wfh.org/fr/abd/carriers/porteuses-la-transmission-de-hemophilie, p.3, 2016.

L. Société-canadienne-de-l-'hémophilie-_-heredite-de-l-'hemophilie, Available at: http://www.hemophilia.ca/fr/troubles-de-la-coagulation/hemophilie-a-et-b/l-heredite-de-lhemophilie, 2015.

M. Lyon, X-chromosome inactivation and human genetic disease, Acta Paediatrica, vol.55, pp.107-112, 2002.
DOI : 10.1111/j.1651-2227.2002.tb03120.x

J. Gitschier, Characterization of the human factor VIII gene, Nature, vol.196, issue.5992, pp.326-330, 1984.
DOI : 10.1038/312326a0

E. G. Tuddenham, Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition, Nucleic Acids Research, vol.22, issue.17, pp.3511-3533, 1994.
DOI : 10.1093/nar/22.17.3511

A. Goodeve, Molecular Genetic Testing of Hemophilia A, Seminars in Thrombosis and Hemostasis, vol.34, issue.06, pp.491-501, 2008.
DOI : 10.1055/s-0028-1103360

C. H. Miller, F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity, Haemophilia, vol.59, issue.Suppl 4, pp.375-382, 2012.
DOI : 10.1111/j.1365-2516.2011.02700.x

V. Institut-de and . Sanitaire, Réseau France Coag: la prise en charge des patients atteints d'une maladie hémorragique héréditaire, le point en 2014, 2015.

A. Mårtensson, U. Tedgård, and R. Ljung, Prenatal diagnosis of haemophilia in Sweden now more commonly used for psychological preparation than termination of pregnancy, Haemophilia, vol.13, issue.Suppl. 4, pp.854-858, 2014.
DOI : 10.1111/hae.12516

M. Trossaert, Compte-rendu de la 5ème journée du Club des biologistes en hémostase, 2013.

L. Pellegrina and C. Emile, Variations physiologiques det pathologiques du facteur VIII: 'le facteur VIII dans tous ses états, BIOTRIBUNE MAG, vol.38, 2011.
DOI : 10.1007/s11834-011-0047-7

F. Peyvandi, J. Oldenburg, and K. D. Friedman, A critical appraisal of one-stage and chromogenic assays of factor VIII activity, Journal of Thrombosis and Haemostasis, vol.119, issue.Suppl. s2, 2015.
DOI : 10.1111/jth.13215

C. Pouplard, The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay, Haemophilia, vol.1, pp.958-962, 2011.
DOI : 10.1111/j.1365-2516.2011.02523.x

B. Delahousse, Diagnostic biologique d'une hémophilie _ cours de DES hématologie_ université de médecine de Tours, 2012.

G. Orphanet, J. Laurian, and Y. , L'hémophilie -encyclopédie Orphanet Grand public, Encyclopédie Orphanet Grand Public, vol.10, 2006.

D. M. Arnold, J. A. Julian, and I. R. Walker, Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up, Blood, vol.108, issue.2, pp.460-464, 2006.
DOI : 10.1182/blood-2005-11-4407

P. M. Mannucci, How I treat age-related morbidities in elderly persons with hemophilia, Blood, vol.114, issue.26, pp.5256-5263, 2009.
DOI : 10.1182/blood-2009-07-215665

B. A. Konkle, The aging patient with hemophilia, American Journal of Hematology, vol.16, issue.Suppl 4, pp.27-32, 2012.
DOI : 10.1002/ajh.23161

S. C. Darby, The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99, Journal of Thrombosis and Haemostasis, vol.102, issue.7, pp.1047-1054, 2004.
DOI : 10.1046/j.1538-7836.2004.00710.x

S. C. Darby, Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV, Blood, vol.110, issue.3, pp.815-825, 2007.
DOI : 10.1182/blood-2006-10-050435

I. Plug, Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study1, Journal of Thrombosis and Haemostasis, vol.75, issue.77, pp.510-516, 1992.
DOI : 10.1046/j.1365-2516.1998.00179.x

M. Canaro, V. Goranova-marinova, and E. Berntorp, The ageing patient with haemophilia, European Journal of Haematology, vol.21, issue.Suppl. 5, pp.17-22, 2015.
DOI : 10.1111/ejh.12497

E. Berntop, Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens, Haemophilia, vol.8, issue.Suppl. 2, pp.1219-1227, 2009.
DOI : 10.1111/j.1365-2516.2009.02077.x

G. Roosendaal, N. W. Jansen, R. Schutgens, and F. P. Lafeber, Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment, Haemophilia, vol.130, issue.Suppl. 3, pp.4-10, 2008.
DOI : 10.1111/j.1365-2516.2008.01882.x

A. Coppola, A. Tagliaferri, D. Capua, M. Franchini, and M. , Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges, Seminars in Thrombosis and Hemostasis, vol.38, issue.01, pp.79-94, 2012.
DOI : 10.1055/s-0031-1300954

T. M. Dale, J. M. Saucedo, and E. C. Rodríguez-merchán, Hemophilic arthropathy of the elbow: prophylaxis, imaging, and the role of invasive??management, Journal of Shoulder and Elbow Surgery, vol.24, issue.10, pp.1669-1678, 2015.
DOI : 10.1016/j.jse.2015.06.018

R. Francecoag, Réseau FranceCoag: cohorte française des patients atteints d'une maladie hémorragique héréditaire, le point en 2011, Inst. Veille Sanit, pp.1-6, 2011.

C. A. Lee, The natural history of HIV disease in haemophilia, Blood Reviews, vol.12, issue.3, pp.135-144, 1998.
DOI : 10.1016/S0268-960X(98)90011-X

C. A. Lee, Safety of coagulation factor concentrates, Haemophilia, vol.86, issue.Suppl. 1, pp.393-401, 1998.
DOI : 10.1046/j.1365-2516.1998.440393.x

C. Négrier, Le traitement de l'hémophilie : des dérivés du plasma à la thérapie génique, pp.17-27, 1996.

S. C. Gouw, J. G. Bom, . Van, H. M. Berg, and . Van-den, Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, vol.109, issue.11, pp.4648-4654, 2007.
DOI : 10.1182/blood-2006-11-056291

. Afssaps, Développement d'inhibiteurs et prise en charge chez les patients hémophiles traités par facteur VIII ou IX d'origine plasmatique ou recombinante, pp.1-69, 2006.

J. Astermark, Overview of Inhibitors, Seminars in Hematology, vol.43, issue.4, pp.3-7, 2006.
DOI : 10.1053/j.seminhematol.2006.03.006

I. National-de-veille-sanitaire, BEH -Premier etat des lieux du suivi de la population hémophile en France (cohorte franceCoag, 1994-2005. Bull. Epidémiologique Hebd. 10 octobre, pp.291-298, 2006.

S. C. Gouw, F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis, Blood, vol.119, issue.12, pp.2922-2934, 2012.
DOI : 10.1182/blood-2011-09-379453

J. Astermark, Prevention and prediction of inhibitor risk, Haemophilia, vol.11, issue.128, pp.38-42, 2012.
DOI : 10.1111/j.1365-2516.2012.02827.x

J. Astermark, FVIII inhibitors: pathogenesis and avoidance, Blood, vol.125, issue.13, pp.2045-2051, 2015.
DOI : 10.1182/blood-2014-08-535328

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416939

S. C. Gouw, Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study, Blood, vol.121, issue.20, pp.4046-4055, 2013.
DOI : 10.1182/blood-2012-09-457036

K. Kurnik, New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development, Haemophilia, vol.110, issue.Suppl. 2, pp.256-262, 2010.
DOI : 10.1111/j.1365-2516.2009.02122.x

J. Astermark, Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report, Haemophilia, vol.7, issue.Suppl.1, pp.747-766, 2010.
DOI : 10.1111/j.1365-2516.2010.02231.x

M. Franchini and P. Mannucci, The History of Hemophilia, Seminars in Thrombosis and Hemostasis, vol.40, issue.05, pp.571-576, 2014.
DOI : 10.1055/s-0034-1381232

S. C. Gouw, Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study, Blood, vol.109, issue.11, pp.4693-4697, 2007.
DOI : 10.1182/blood-2006-11-056317

S. C. Gouw, Factor VIII Products and Inhibitor Development in Severe Hemophilia A, New England Journal of Medicine, vol.368, issue.3, pp.231-239, 2013.
DOI : 10.1056/NEJMoa1208024

J. Goudemand, Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A, Blood, vol.107, issue.1, pp.46-51, 2006.
DOI : 10.1182/blood-2005-04-1371

P. M. Mannucci, Back to the future: a recent history of haemophilia treatment, Haemophilia, vol.110, issue.2, pp.10-18, 2008.
DOI : 10.1111/j.1538-7836.2005.01258.x

M. Husson, Facteurs antihémophiliques: traitement substitutif de l'hémophilie A et B, Doss. CNHIM Rev. Dévaluation Sur Médicam. XXIV, p.82, 2003.

R. Des and C. Du-produit-factane, Available at: http://agenceprd .ansm.sante.fr, R0236106.htm, p.30, 2016.

. Octapharma, Mentions légales Octanate 50 et 100 UI/ml, 2013.

S. Chtourou, A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates, Vox Sanguinis, vol.4, issue.0, pp.327-337, 2007.
DOI : 10.1111/j.1423-0410.2006.00792.x

A. Lfb, Brochure d'information Patient -Factane 200 UI/ml, 2014.

M. Burnouf-radesovich, Process for the preparation of a concentrate from FVIII-factor von Willebrand of blood coagulation from the whole plasma

M. Ezban, K. Vad, and M. Kjalke, ) - from design to clinical proof of concept, European Journal of Haematology, vol.7, issue.suppl 2, pp.369-376, 2014.
DOI : 10.1111/ejh.12366

S. W. Pipe, Functional roles of the factor VIII B domain, Haemophilia, vol.109, issue.Suppl 2, pp.1187-1196, 2009.
DOI : 10.1111/j.1365-2516.2009.02026.x

. Octapharma, Brochure promotionnelle Octanate-Success is Overcoming Challenges in life, 2007.

A. Octapharma, Available at: http://www.octapharma.com/en/about/production/plasma, Plasmahtml, p.13, 2016.

B. Polack, EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France, Transfusion, vol.80, issue.Suppl 4, 2015.
DOI : 10.1111/trf.13016

URL : https://hal.archives-ouvertes.fr/hal-01463671

. Goudemand, Treatment of patients with inhibitors: cost issues, Haemophilia, vol.2, issue.6, pp.397-401, 1999.
DOI : 10.1046/j.1365-2516.1998.00129.x

A. Gringeri, L. G. Mantovani, L. Scalone, and P. M. Mannucci, Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group, Blood, vol.102, issue.7, pp.2358-2363, 2003.
DOI : 10.1182/blood-2003-03-0941

E. Berntorp and A. D. Shapiro, Modern haemophilia care, The Lancet, vol.379, issue.9824, pp.1447-1456, 2012.
DOI : 10.1016/S0140-6736(11)61139-2

E. Berntorp, History of prophylaxis, Haemophilia, vol.18, issue.Suppl. 4, pp.163-165, 2013.
DOI : 10.1111/hae.12100

M. J. Manco-johnson, Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, New England Journal of Medicine, vol.357, issue.6, pp.535-544, 2007.
DOI : 10.1056/NEJMoa067659

L. A. Valentino, Considerations in individualizing prophylaxis in patients with haemophilia A. Haemoph. Off, J. World Fed. Hemoph, vol.20, pp.607-615, 2014.

M. Carcao and A. Srivastava, Factor VIII/factor IX prophylaxis for severe hemophilia, Seminars in Hematology, vol.53, issue.1, 2015.
DOI : 10.1053/j.seminhematol.2015.10.006

R. Biggs, Christmas Disease, BMJ, vol.2, issue.4799, pp.1378-1382, 1952.
DOI : 10.1136/bmj.2.4799.1378

A. Liberati, The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration, J. Clin

D. G. Walker, Best Practices for Conducting Economic Evaluations in Health Care: A Systematic Review of Quality Assessment Tools, Agency for Healthcare Research and Quality, p.2012

D. Husereau, Consolidated Health Economic Evaluation Reporting Standards (CHEERS)???Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force, Value in Health, vol.16, issue.2, pp.231-250, 2013.
DOI : 10.1016/j.jval.2013.02.002

L. Torre and G. H. , Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine Long-term outcome of individualized prophylactic treatment of children with severe haemophilia, J. Public Health Br. J. Haematol, vol.103111, issue.112, pp.561-565, 2001.

J. Ahnström, E. Berntorp, K. Lindvall, and S. Björkman, A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia, Haemophilia, vol.23, issue.2, pp.689-697, 2004.
DOI : 10.1111/j.1538-7836.2004.00528.x

K. Van-dijk, Factor VIII half-life and clinical phenotype of severe hemophilia A, Haematologica, vol.90, pp.494-498, 2005.

K. Van-dijk, K. Fischer, J. G. Van-der-bom, D. E. Grobbee, and H. M. Van-den-berg, Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed, Haemophilia, vol.2, issue.3, pp.438-443, 2005.
DOI : 10.1093/nar/26.1.216

B. M. Feldman, Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study, Journal of Thrombosis and Haemostasis, vol.14, issue.3, pp.1228-1236, 2006.
DOI : 10.1111/j.1538-7836.2004.00653.x

L. A. Valentino, A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management, Journal of Thrombosis and Haemostasis, vol.7, issue.Suppl. 3, pp.359-367, 2012.
DOI : 10.1111/j.1538-7836.2011.04611.x

K. Lindvall, Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy, Haemophilia, vol.17, issue.Suppl. 2, pp.855-859, 2012.
DOI : 10.1111/j.1365-2516.2012.02879.x

A. J. Reininger and H. Chehadeh, The principles of PK-tailored prophylaxis, Hämostaseologie, vol.33, pp.32-35, 2013.

C. Santoro, E. Baldacci, C. Mercanti, and M. G. Mazzucconi, Tailored versus standard dose prophylaxis in children with hemophilia A, Semin. Thromb. Hemost, vol.39, pp.711-722, 2013.

E. Berntorp, G. Spotts, L. Patrone, and B. M. Ewenstein, Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method, Biologics: Targets and Therapy, vol.8, pp.115-127, 2014.
DOI : 10.2147/BTT.S53456

S. Fernandes, M. Carvalho, M. Lopes, and F. Araújo, Impact of an individualized prophylaxis approach on young adults with severe hemophilia, Semin. Thromb. Hemost, vol.40, pp.785-789, 2014.

B. Sorensen and &. , Rationale for individualizing haemophilia care, Blood Coagulation & Fibrinolysis, vol.26, issue.8, 2014.
DOI : 10.1097/MBC.0000000000000225

M. D. Carcao and A. Iorio, Individualizing factor replacement therapy in severe hemophilia

P. Petrini, L. A. Valentino, A. Gringeri, W. M. Re, and B. Ewenstein, Individualizing prophylaxis in hemophilia: a review, Expert Review of Hematology, vol.8, issue.2, pp.237-246, 2015.
DOI : 10.1586/17474086.2015.1002465

M. Stemberger, E. Schmit, K. Kurnik, and M. Spannagl, Motivational effects of top-rope climbing therapy under individualized prophylaxis: a pilot study in young adults with severe haemophilia, Haemophilia, vol.21, issue.6, pp.504-507, 2015.
DOI : 10.1111/hae.12773

N. Zourikian, C. Merlen, A. Bonnefoy, J. St-louis, and G. Rivard, Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study, Haemophilia, vol.82, issue.Suppl. 3, pp.177-183, 2016.
DOI : 10.1111/hae.12869

I. Jaisson-hot, Méthodes d'évaluation médico-économique: application à la cancérologie, Bull Cancer, pp.939-945, 2003.

A. H. Miners, C. A. Sabin, K. H. Tolley, and C. A. Lee, Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia, PharmacoEconomics, vol.3, issue.4, pp.759-774, 2002.
DOI : 10.2165/00019053-200220110-00005

A. Miners, Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A, Haemophilia, vol.42, issue.Suppl. 2, pp.881-887, 2009.
DOI : 10.1111/j.1365-2516.2009.02019.x

G. L. Colombo, D. Matteo, S. Mancuso, M. E. Santagostino, and E. , Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A, ClinicoEconomics and Outcomes Research, vol.3, pp.55-61, 2011.
DOI : 10.2147/CEOR.S16670

N. Risebrough, Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A, Haemophilia, vol.9, issue.4
DOI : 10.1111/j.1365-2516.2008.01664.x

A. Farrugia, Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment, Haemophilia, vol.11, issue.Suppl 2, pp.228-238, 2013.
DOI : 10.1111/hae.12121

A. A. Daliri, H. Haghparast, and J. Mamikhani, Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran, International Journal of Technology Assessment in Health Care, vol.9, issue.04, pp.584-587, 2009.
DOI : 10.1097/01.mbc.0000178830.39526.ff

P. S. Smith, S. M. Teutsch, P. A. Shaffer, H. Rolka, and B. Evatt, Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis, The Journal of Pediatrics, vol.129, issue.3, pp.424-431, 1996.
DOI : 10.1016/S0022-3476(96)70076-8

W. Liou, Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan, Haemophilia, vol.241, issue.Suppl 1, pp.45-54, 2011.
DOI : 10.1111/j.1365-2516.2010.02367.x

B. Lippert, Cost effectiveness of haemophilia treatment: a cross-national assessment, Blood Coagulation & Fibrinolysis, vol.16, issue.7, pp.477-485, 2005.
DOI : 10.1097/01.mbc.0000178830.39526.ff

A. H. Miners, C. A. Sabin, K. H. Tolley, and C. A. Lee, Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease, Journal of Internal Medicine, vol.8, issue.6, pp.515-522, 1998.
DOI : 10.1046/j.1365-2141.1996.420960.x

A. Farrugia, Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment, Haemophilia, vol.11, issue.Suppl 2, pp.228-238, 2013.
DOI : 10.1111/hae.12121

B. Polack, EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France, Transfusion, vol.80, issue.Suppl 4, pp.1787-1797, 2015.
DOI : 10.1111/trf.13016

URL : https://hal.archives-ouvertes.fr/hal-01463671

M. Drummond, M. Sculpher, G. Torrance, B. O-'brien, and G. Stoddart, Methods for the economic evaluation of health care programmes

M. Massetti, A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments, Journal of Market Access & Health Policy, vol.11, issue.1, 2015.
DOI : 10.3402/jmahp.v3.24966

I. M. Nilsson, E. Berntorp, T. Löfqvist, and H. Pettersson, Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B, Journal of Internal Medicine, vol.23, issue.3, pp.25-32, 1992.
DOI : 10.1111/j.1365-2796.1992.tb00546.x

P. W. Collins, Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A, Journal of Thrombosis and Haemostasis, vol.10, issue.Suppl. 4, pp.413-420, 2009.
DOI : 10.1111/j.1538-7836.2008.03270.x

P. W. Collins, Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, Journal of Thrombosis and Haemostasis, vol.8, issue.Suppl. 1, pp.269-275, 2010.
DOI : 10.1111/j.1538-7836.2009.03703.x

V. S. Blanchette, Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients, Journal of Thrombosis and Haemostasis, vol.3, issue.8, pp.1319-1326, 2008.
DOI : 10.1111/j.1538-7836.2008.03032.x

N. Simon, C. L. Guellec, and S. Laporte, Analyse pharmacocinétique de population, Médecine Thérapeutique, vol.11, pp.212-218, 2005.

S. Urien, La pharmacocinétique de population, aspects fondamentaux, Lett. Pharmacol, vol.17, pp.97-102, 2003.

P. Petrini, L. A. Valentino, A. Gringeri, W. M. Re, and B. Ewenstein, Individualizing prophylaxis in hemophilia: a review, Expert Review of Hematology, vol.8, issue.2, pp.237-246, 2015.
DOI : 10.1586/17474086.2015.1002465

B. Sorenson, Rationale for individualizing haemophilia care, Blood Coagulation & Fibrinolysis, vol.26, issue.8, pp.0-00, 2014.
DOI : 10.1097/MBC.0000000000000225

M. Valente, Health economic models in hemophilia A and utility assumptions from a clinician's perspective, Pediatric Blood & Cancer, vol.12, issue.10, pp.1826-1831, 2015.
DOI : 10.1002/pbc.25543

K. Saxena, Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial, Haemophilia, vol.4, issue.Suppl. 3, 2016.
DOI : 10.1111/hae.12952

F. Peyvandi, Paper: Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study Available at: https://ash.confex.com/ash, p.3, 2015.

I. F. Bello, Bayesian Estimation of Pharmacokinetic Parameters in Children and Adolescents with Severe Hemophilia: A Single Center Experience, Blood, vol.126, pp.3534-3534, 2015.

P. Haemophilia, |. Tool, and . Advate, Available at: http://advatepro.com/global/haemophilia-patient-tools/mypkfit-pk-dosing-tool, p.3, 2016.